Siemens closed its last fiscal year with an attributed net profit of 8.488 billion euros, representing a decline of 11.8% compared with the previous year, when the accounts of the German engineering conglomerate recorded an exceptional gain of 2.100 billion from the sale of Innomotics.
At the same time, the result from continuing operations of the multinational rose to 9.400 billion euros by the end of the fiscal year, an advance of 12.9% year-on-year.
Siemens’ total revenue for the course of the fiscal year reached 83.372 billion euros, 6% more than a year earlier, while incoming orders jumped 22%, to an all-time high of 108.159 billion.
Development by business divisions
By area of activity, Siemens’ digital business increased its annual sales by 11%, to 19.677 billion euros, while the intelligent infrastructure division generated 25.088 billion, 9% more. In turn, Siemens’ mobility segment increased its turnover by 4%, to 12.963 billion; and the medical technology unit reached revenue of about 23.630 billion, 1% above the preceding fiscal year.
Between July and September, which corresponds to the fourth fiscal quarter for the German group, Siemens’ attributed net profit stood at 2.161 billion euros, 33.5% more than in the same period of the previous year. In those three months, the business volume advanced 11% year-on-year, to 23.683 billion euros, and orders once again set a maximum, adding up to 34.771 billion, 58% more.
"Fiscal year 2026 was an exceptional year for Siemens," said Roland Busch, chairman and chief executive officer of the company, who believes that industrial AI represents "an exceptional growth opportunity".
"Through the continued expansion of industrial AI, we are driving our next phase of profitable growth," the executive added.
Dividend up and Siemens Healthineers spin-off
For its part, Veronika Bienert, Siemens’ chief financial officer, stated that, after concluding fiscal year 2026 with record figures in orders, profits, and free cash flow, the group will propose to increase the dividend to 5.50 euros per share, from the 5.35 euros paid one year earlier, in line with its policy of progressive remuneration to shareholders.
In addition, in the context of the already communicated split, Siemens intends to transfer 34.1% of its stake in Siemens Healthineers to shareholders, at the rate of one share of Siemens Healthineers for every two shares of Siemens.
As part of this transaction, which is projected for 2027, Siemens Healthineers will be renamed Healthineers and will begin a brand transition process with an estimated duration of three years.
The transaction, with which Siemens aims to stop consolidating the healthcare technology business in its financial statements, will be submitted for approval by the shareholders of both companies at their respective general meetings in February 2027. In turn, the change of company name will have to be supported by the shareholders’ meeting of Siemens Healthineers.
Projections for fiscal year 2027
With a view to fiscal year 2027, Siemens expects the global economy to maintain its expansion, with GDP growth supported primarily by sustained investment in AI and digital infrastructure, public spending programs and a greater recovery of industrial activity.
In this context, the projections of the German group, excluding the effects linked to the deconsolidation of Siemens Healthineers that is planned, point to an increase in comparable revenue of between 9% and 11%, as well as to basic earnings per share, calculated from net profit before purchase price allocation (pre-PPA EPS), of between €10.20 and €10.80 in fiscal year 2027, compared with €9.27 recorded in fiscal year 2026.